SLU-PP-332 activates estrogen receptor-related orphan receptors, increasing energy expenditure, fatty acid oxidation, and decreasing fat mass accumulation. The drug enhances mitochondrial function and cellular respiration in skeletal muscle cell lines, increases the expression of an estrogen receptor-related orphan receptor target gene, and enhances mitochondrial respiration in C2C12 myocytes. The drug also increases oxidative fibers in skeletal muscle and improves exercise endurance in C57BL/6J mice.
{"title":"New hopes on \"SLU-PP-332\" as an effective agent for weight loss with indirect kidney protection efficacy; a nephrology point of view","authors":"Hamid Nasri","doi":"10.34172/jre.2024.25143","DOIUrl":"https://doi.org/10.34172/jre.2024.25143","url":null,"abstract":"SLU-PP-332 activates estrogen receptor-related orphan receptors, increasing energy expenditure, fatty acid oxidation, and decreasing fat mass accumulation. The drug enhances mitochondrial function and cellular respiration in skeletal muscle cell lines, increases the expression of an estrogen receptor-related orphan receptor target gene, and enhances mitochondrial respiration in C2C12 myocytes. The drug also increases oxidative fibers in skeletal muscle and improves exercise endurance in C57BL/6J mice.","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"26 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139633363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vitamin D is crucial for maintaining optimal health. This review study evaluates health problems related to deficiency and ways to maintain sufficient levels. We conducted a review of the association between vitamin D inadequacy and various diseases, explored the various sources of vitamin D and the risk factors associated with vitamin D insufficiency, examined the consequences of insufficient vitamin D levels, and assessed the potential benefits of taking vitamin D supplements for promoting good health. A literature review demonstrated that maintaining sufficient levels of vitamin D is essential for improving health and preventing various diseases. Vitamin D deficiency is a common condition, and it can be addressed by consuming a balanced diet, getting regular exposure to sunlight, or taking supplements as necessary.
维生素 D 对保持最佳健康状态至关重要。本综述研究评估了与维生素 D 缺乏有关的健康问题以及保持足够水平的方法。我们回顾了维生素 D 不足与各种疾病之间的关系，探讨了维生素 D 的各种来源以及与维生素 D 不足相关的风险因素，研究了维生素 D 水平不足的后果，并评估了服用维生素 D 补充剂对促进健康的潜在益处。文献综述表明，保持足够水平的维生素 D 对改善健康和预防各种疾病至关重要。维生素 D 缺乏症是一种常见病，可通过均衡饮食、经常晒太阳或服用必要的补充剂来解决。
{"title":"Vitamin D and its role in health; A review of mechanisms, risk factors, sources, and health benefits","authors":"Moloud Alsadat Mousavi, M. Hosseinifard, Maryam Aligholizadeh, Siavash Sangi, Zahra Kordeyazdi, Faraz Zandiyeh","doi":"10.34172/jre.2024.25133","DOIUrl":"https://doi.org/10.34172/jre.2024.25133","url":null,"abstract":"Vitamin D is crucial for maintaining optimal health. This review study evaluates health problems related to deficiency and ways to maintain sufficient levels. We conducted a review of the association between vitamin D inadequacy and various diseases, explored the various sources of vitamin D and the risk factors associated with vitamin D insufficiency, examined the consequences of insufficient vitamin D levels, and assessed the potential benefits of taking vitamin D supplements for promoting good health. A literature review demonstrated that maintaining sufficient levels of vitamin D is essential for improving health and preventing various diseases. Vitamin D deficiency is a common condition, and it can be addressed by consuming a balanced diet, getting regular exposure to sunlight, or taking supplements as necessary.","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"53 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139633228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Behnoosh Mohammadi Jazi, P. Nematollahy, Noushin Maktoobian
Introduction: Lymphocytosis is characterized by an elevation in the absolute lymphocyte count (ALC) to over 4000 lymphocytes per microliter among adults. In lymphocytosis, the important matter is whether lymphocytosis is a benign reactive condition or a neoplastic lymphoproliferative disorder (LPD), which can be determined by immunophenotyping methods by flow cytometry. Objectives: Due to the need to use flow cytometry to confirm the diagnosis of patients with lymphocytosis, the purpose of this study was to compare the frequency of benign reactive lymphocytosis and LPDs in patients with persistent lymphocytosis using flow cytometry in the peripheral blood and report the results based on the patient’s demographic characteristics. Materials and Methods: This study was a cross-sectional study and the study population was all peripheral blood samples referred to Seyed Al-Shohada hospital in Isfahan to study the cause of absolute and persistent lymphocytosis by immunophenotyping analysis through flow cytometry between 2015 and 2020. Inclusion criteria were patients over 18 years of age with absolute lymphocytosis in complete blood count (CBC) or peripheral blood smear (PBS) who were examined by flow cytometry. Results: This study involved 222 samples, 139 (62.6%) of the cases were male. The mean age was 60.41 (15.91) years. All samples had absolute lymphocytosis and were divided into two groups: benign, with 62 (27.9%), and malignant, with 160 (72.1%). Conclusion: The relationship between gender and malignancy showed that the male gender was associated with an increased risk of malignancy. The mean age between the two groups of malignant and benign was determined by independent t test, and it was shown that the mean (±standard deviation) age of malignant cases is higher than the mean age of benign cases. It is recommended that cases of suspected lymphoproliferative cases and cases with cell counts below the lymphocytosis threshold be investigated in separate studies.
{"title":"Evaluation of the frequency of benign reactive lymphocytosis and lymphoproliferative disorders by flow cytometry in patients with persistent lymphocytosis in peripheral blood","authors":"Behnoosh Mohammadi Jazi, P. Nematollahy, Noushin Maktoobian","doi":"10.34172/jre.2023.25131","DOIUrl":"https://doi.org/10.34172/jre.2023.25131","url":null,"abstract":"Introduction: Lymphocytosis is characterized by an elevation in the absolute lymphocyte count (ALC) to over 4000 lymphocytes per microliter among adults. In lymphocytosis, the important matter is whether lymphocytosis is a benign reactive condition or a neoplastic lymphoproliferative disorder (LPD), which can be determined by immunophenotyping methods by flow cytometry. Objectives: Due to the need to use flow cytometry to confirm the diagnosis of patients with lymphocytosis, the purpose of this study was to compare the frequency of benign reactive lymphocytosis and LPDs in patients with persistent lymphocytosis using flow cytometry in the peripheral blood and report the results based on the patient’s demographic characteristics. Materials and Methods: This study was a cross-sectional study and the study population was all peripheral blood samples referred to Seyed Al-Shohada hospital in Isfahan to study the cause of absolute and persistent lymphocytosis by immunophenotyping analysis through flow cytometry between 2015 and 2020. Inclusion criteria were patients over 18 years of age with absolute lymphocytosis in complete blood count (CBC) or peripheral blood smear (PBS) who were examined by flow cytometry. Results: This study involved 222 samples, 139 (62.6%) of the cases were male. The mean age was 60.41 (15.91) years. All samples had absolute lymphocytosis and were divided into two groups: benign, with 62 (27.9%), and malignant, with 160 (72.1%). Conclusion: The relationship between gender and malignancy showed that the male gender was associated with an increased risk of malignancy. The mean age between the two groups of malignant and benign was determined by independent t test, and it was shown that the mean (±standard deviation) age of malignant cases is higher than the mean age of benign cases. It is recommended that cases of suspected lymphoproliferative cases and cases with cell counts below the lymphocytosis threshold be investigated in separate studies.","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"9 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139637243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Contrast-associated acute renal injury is a common complication that occurs after the administration of contrast media for diagnostic or therapeutic purposes. It is characterized by a sudden decline in kidney function within 48-72 hours after the administration of contrast media. The incidence of contrast-associated acute renal injury varies depending on the patient’s risk factors and the type and amount of contrast media used. Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a group of antidiabetic drugs that inhibit the reabsorption of glucose in the nephrons, running to raise urinary glucose excretion and improve glycemic control. Recent studies have shown that SGLT2 inhibitors may have a protective effect against contrast-associated acute renal injury. Preventive measures for contrast-associated acute renal injury include hydration, minimizing contrast volume and rate of administration, and avoiding contrast in high-risk patients. The administration of SGLT2 inhibitors may also be a useful preventive measure in patients at risk for contrast-associated acute renal injury.
{"title":"Contrast-induced acute kidney injury; possible ameliorative effect of sodium-glucose co-transporter 2 inhibitors","authors":"Hamid Nasri","doi":"10.34172/jre.2024.25142","DOIUrl":"https://doi.org/10.34172/jre.2024.25142","url":null,"abstract":"Contrast-associated acute renal injury is a common complication that occurs after the administration of contrast media for diagnostic or therapeutic purposes. It is characterized by a sudden decline in kidney function within 48-72 hours after the administration of contrast media. The incidence of contrast-associated acute renal injury varies depending on the patient’s risk factors and the type and amount of contrast media used. Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a group of antidiabetic drugs that inhibit the reabsorption of glucose in the nephrons, running to raise urinary glucose excretion and improve glycemic control. Recent studies have shown that SGLT2 inhibitors may have a protective effect against contrast-associated acute renal injury. Preventive measures for contrast-associated acute renal injury include hydration, minimizing contrast volume and rate of administration, and avoiding contrast in high-risk patients. The administration of SGLT2 inhibitors may also be a useful preventive measure in patients at risk for contrast-associated acute renal injury.","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"6 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139632062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Contrast-induced nephropathy (CIN) is a well-known complication of contrast media administration for diagnostic and therapeutic purposes. The incidence of CIN has increased with the widespread use of diagnostic imaging and contrast media. CIN is a pathological condition that typically occurs within 48 hours of exposure to contrast material and results in an increase in serum creatinine levels of more than 44 µmol/L (0.5 mg/dL) or 25% above baseline or an increase in serum creatinine of more than 1.5 times the baseline level within 7 days of exposure to contrast material or a reduction in urine output to less than 0.5 mL/h for at least 6 hours after exposure to contrast material. The mechanism of CIN is not fully understood, but it is thought to involve direct nephrotoxic effects of contrast particles, hemodynamic changes, hypoxia and oxidative stress, apoptosis, inflammation, and immune responses. Prevention of CIN involves identifying the risk factors and taking appropriate measures to mitigate them. Currently, there is no definitive treatment for CIN, and treatment is mainly symptomatic, with supportive care being the mainstay. Experimental treatments such as renal replacement therapy, extracorporeal blood purification, and stem cell therapy are being investigated, but their clinical efficacy is yet to be established.
{"title":"Contrast-induced nephropathy; an update on pathophysiology","authors":"Yasaman Yadollahi Fars, Razieh Moghadasi, Shokouh Shayanpour","doi":"10.34172/jre.2023.25099","DOIUrl":"https://doi.org/10.34172/jre.2023.25099","url":null,"abstract":"Contrast-induced nephropathy (CIN) is a well-known complication of contrast media administration for diagnostic and therapeutic purposes. The incidence of CIN has increased with the widespread use of diagnostic imaging and contrast media. CIN is a pathological condition that typically occurs within 48 hours of exposure to contrast material and results in an increase in serum creatinine levels of more than 44 µmol/L (0.5 mg/dL) or 25% above baseline or an increase in serum creatinine of more than 1.5 times the baseline level within 7 days of exposure to contrast material or a reduction in urine output to less than 0.5 mL/h for at least 6 hours after exposure to contrast material. The mechanism of CIN is not fully understood, but it is thought to involve direct nephrotoxic effects of contrast particles, hemodynamic changes, hypoxia and oxidative stress, apoptosis, inflammation, and immune responses. Prevention of CIN involves identifying the risk factors and taking appropriate measures to mitigate them. Currently, there is no definitive treatment for CIN, and treatment is mainly symptomatic, with supportive care being the mainstay. Experimental treatments such as renal replacement therapy, extracorporeal blood purification, and stem cell therapy are being investigated, but their clinical efficacy is yet to be established.","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78917137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Farinaz Fattahi, M. Farnia, Bareza Rezaei, Hooman Rafiei, Aisan Ghasemi Oskui, A. Amiri, Mohammad Reza Rezaei
Introduction: Kidney dysfunction, coagulopathy disorders, and lung involvement are the most common disorders caused by the COVID-19 virus. Objectives: This study aimed to investigate the correlation of lung involvement severity with kidney dysfunction and coagulopathy disorders in COVID-19 patients. Patients and Methods: This descriptive-analytical study was conducted on 97 patients with COVID-19 referred to Imam Reza hospital in Kermanshah from December 2020 to June 2021. Lung involvement severity, kidney function tests, and coagulation laboratory data were collected. Logistic regression test was conducted to explore the correlation between lung involvement with kidney dysfunction and coagulopathy disorders. Results: Out of 97 patients, 53 (54.6%) were male, with a mean age of 59.31 ± 16.44 years. The correlation between lung involvement severity with kidney function tests, including, blood urea nitrogen, serum creatinine, and coagulation factors, including prothrombin time (PT), partial thromboplastin time (PTT), and D-dimer, were significant (P > 0.05). Lung involvement severity significantly predicted kidney dysfunction and coagulopathy disorders. Conclusion: Lung involvement severity would be able to predict kidney dysfunction and coagulopathy disorders in patients with COVID-19.
{"title":"COVID-19 patients’ lung involvement severity as a predictor of kidney dysfunction and coagulopathy disorders","authors":"Farinaz Fattahi, M. Farnia, Bareza Rezaei, Hooman Rafiei, Aisan Ghasemi Oskui, A. Amiri, Mohammad Reza Rezaei","doi":"10.34172/jre.2023.25096","DOIUrl":"https://doi.org/10.34172/jre.2023.25096","url":null,"abstract":"Introduction: Kidney dysfunction, coagulopathy disorders, and lung involvement are the most common disorders caused by the COVID-19 virus. Objectives: This study aimed to investigate the correlation of lung involvement severity with kidney dysfunction and coagulopathy disorders in COVID-19 patients. Patients and Methods: This descriptive-analytical study was conducted on 97 patients with COVID-19 referred to Imam Reza hospital in Kermanshah from December 2020 to June 2021. Lung involvement severity, kidney function tests, and coagulation laboratory data were collected. Logistic regression test was conducted to explore the correlation between lung involvement with kidney dysfunction and coagulopathy disorders. Results: Out of 97 patients, 53 (54.6%) were male, with a mean age of 59.31 ± 16.44 years. The correlation between lung involvement severity with kidney function tests, including, blood urea nitrogen, serum creatinine, and coagulation factors, including prothrombin time (PT), partial thromboplastin time (PTT), and D-dimer, were significant (P > 0.05). Lung involvement severity significantly predicted kidney dysfunction and coagulopathy disorders. Conclusion: Lung involvement severity would be able to predict kidney dysfunction and coagulopathy disorders in patients with COVID-19.","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"45 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82567434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Implication for health policy/practice/research/medical education: Vitamin D plays an essential role in the management of COVID-19.
对卫生政策/实践/研究/医学教育的影响:维生素D在COVID-19的管理中发挥着至关重要的作用。
{"title":"Role of vitamin D in COVID-19 management","authors":"S. Zandifar","doi":"10.34172/jre.2023.25091","DOIUrl":"https://doi.org/10.34172/jre.2023.25091","url":null,"abstract":"Implication for health policy/practice/research/medical education: Vitamin D plays an essential role in the management of COVID-19.","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76181712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The important renal endocrine aspect implicated in gym nephropathy is the activation of the renin-angiotensin-aldosterone system (RAAS). Intense exercise can lead to increased sympathetic nervous system activity, resulting in the release of renin from the juxtaglomerular cells in the kidneys. Renin acts on angiotensinogen, leading to the generation of angiotensin II, a potent vasoconstrictor. Angiotensin II stimulates the secretion of aldosterone from the adrenal glands, which promotes sodium reabsorption and potassium excretion in the kidneys. The persistent activation of the RAAS in gym nephropathy may contribute to renal damage by causing vasoconstriction and promoting renal inflammation.
{"title":"Renal endocrine aspects of exercise-induced acute kidney injury (gym nephropathy)","authors":"M. Moonesan","doi":"10.34172/jre.2023.25128","DOIUrl":"https://doi.org/10.34172/jre.2023.25128","url":null,"abstract":"The important renal endocrine aspect implicated in gym nephropathy is the activation of the renin-angiotensin-aldosterone system (RAAS). Intense exercise can lead to increased sympathetic nervous system activity, resulting in the release of renin from the juxtaglomerular cells in the kidneys. Renin acts on angiotensinogen, leading to the generation of angiotensin II, a potent vasoconstrictor. Angiotensin II stimulates the secretion of aldosterone from the adrenal glands, which promotes sodium reabsorption and potassium excretion in the kidneys. The persistent activation of the RAAS in gym nephropathy may contribute to renal damage by causing vasoconstriction and promoting renal inflammation.","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78472918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jafar Kolahi, Soleyman Alivand, N. Alivand, Sara Dehghan, Farzaneh Barkhordari Ahmadi, Najmeh Parsai, Mohammad Hossein Taklif, Reyhaneh Sadeghian, H. Mardanparvar
Introduction: The correlation between hyperuricemia and chronic kidney disease (CKD) is an approval issue; this study aimed to evaluate the effect of allopurinol on serum uric acid levels in patients with diabetic nephropathy, with the review of randomized clinical trials (RCTs). Materials and Methods: This meta-analysis study was conducted on RCTs in diabetic nephropathy patients, which evaluated the effect of allopurinol on serum uric acid levels. Data were collected by searching international databases and Google Scholar search engines until May 2023. STATA 14 software and the random effects model were conducted to analyze the data. A P value less than 0.05 was considered significant. Results: In this study, five studies with a sample size of 942 patients were assessed. The effect of allopurinol on serum uric acid in comparison to the placebo group deduced that the standard mean difference between the allopurinol group and placebo group was -1.55 mg/dL, which was statistically significant (CI: -2.07 to -1.02). Conclusion: Allopurinol through its uric acid lowering effect would be beneficial for patients with diabetic nephropathy in preventing the progression of CKD. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID: CRD42023412051).
{"title":"The effect of allopurinol on serum uric acid levels in patients with diabetic nephropathy; a systematic review and meta-analysis on randomized clinical trials","authors":"Jafar Kolahi, Soleyman Alivand, N. Alivand, Sara Dehghan, Farzaneh Barkhordari Ahmadi, Najmeh Parsai, Mohammad Hossein Taklif, Reyhaneh Sadeghian, H. Mardanparvar","doi":"10.34172/jre.2023.25094","DOIUrl":"https://doi.org/10.34172/jre.2023.25094","url":null,"abstract":"Introduction: The correlation between hyperuricemia and chronic kidney disease (CKD) is an approval issue; this study aimed to evaluate the effect of allopurinol on serum uric acid levels in patients with diabetic nephropathy, with the review of randomized clinical trials (RCTs). Materials and Methods: This meta-analysis study was conducted on RCTs in diabetic nephropathy patients, which evaluated the effect of allopurinol on serum uric acid levels. Data were collected by searching international databases and Google Scholar search engines until May 2023. STATA 14 software and the random effects model were conducted to analyze the data. A P value less than 0.05 was considered significant. Results: In this study, five studies with a sample size of 942 patients were assessed. The effect of allopurinol on serum uric acid in comparison to the placebo group deduced that the standard mean difference between the allopurinol group and placebo group was -1.55 mg/dL, which was statistically significant (CI: -2.07 to -1.02). Conclusion: Allopurinol through its uric acid lowering effect would be beneficial for patients with diabetic nephropathy in preventing the progression of CKD. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID: CRD42023412051).","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"287 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86744417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nephroceuticals are natural or pharmacologically active compounds used to manage and even reverse certain kidney diseases. The term "nephroceuticals" is relatively new, although the study of utilizing natural or active compounds to manage kidney disease has been emerging for many years. Nephroceuticals have shown promise in supporting conventional therapies such as dialysis and kidney transplantation, and are purported to have fewer adverse effects compared to conventional chemical compounds.
{"title":"Nephroceuticals as a new hope for the treatment of kidney diseases","authors":"M. Zahmatkesh","doi":"10.34172/jre.2023.25112","DOIUrl":"https://doi.org/10.34172/jre.2023.25112","url":null,"abstract":"Nephroceuticals are natural or pharmacologically active compounds used to manage and even reverse certain kidney diseases. The term \"nephroceuticals\" is relatively new, although the study of utilizing natural or active compounds to manage kidney disease has been emerging for many years. Nephroceuticals have shown promise in supporting conventional therapies such as dialysis and kidney transplantation, and are purported to have fewer adverse effects compared to conventional chemical compounds.","PeriodicalId":16964,"journal":{"name":"Journal of Renal Endocrinology","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84453539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：